• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Syndax Pharmaceuticals (SNDX) Could Be 40% Undervalued As Pipeline Updates Sharpen Growth Story

    Simply Wall St·07/16/2026 13:41:43
    Listen to the news

    Syndax Pharmaceuticals (SNDX) put its research pipeline in the spotlight with an R&D event focused on new oncology and fibrosis projects, a development that has drawn fresh attention to the stock.

    See our latest analysis for Syndax Pharmaceuticals.

    The R&D event comes after a mixed stretch for Syndax Pharmaceuticals, with the share price down 2.53% over the last day and 4.23% over the past week, but showing a 27.27% 1 month share price return and a 1 year total shareholder return of 154.27%. This suggests recent pipeline updates are being weighed against an already strong longer term run.

    If you are looking beyond Syndax for other healthcare-focused opportunities tied to new therapies and data readouts, this could be a good moment to check out 40 healthcare AI stocks

    Syndax Pharmaceuticals has already rewarded early believers, but a 1 year total shareholder return above 150% and recent R&D catalysts raise a fresh debate: is most of the upside already priced in, or is the market still behind the story?

    Most Popular Narrative: 40.5% Undervalued

    With Syndax Pharmaceuticals last closing at $23.52 against a narrative fair value of $39.50, the current price sits well below what this widely followed framework implies, putting its R&D event into a sharper context.

    Late-stage pipeline advancements (including frontline trials, lifecycle management, and expansion into new indications like IPF for Niktimvo), coupled with strong clinical data and market-leading positions in precision oncology, provide robust long-term growth avenues aligned with surging demand for innovative, targeted therapies, supporting sustained multi-year earnings momentum.

    Read the complete narrative.

    Want to understand why this narrative treats Syndax Pharmaceuticals as materially undervalued? It leans on steep revenue expansion, a swing into profitability, and a rich future earnings multiple. Curious which specific assumptions have the most impact on that $39.50 figure, and how sensitive the story is to those inputs? The full narrative lays out the numbers and the tension between ambitious growth and concentrated product risk.

    Result: Fair Value of $39.50 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, Syndax Pharmaceuticals still faces meaningful risks, including heavy dependence on Revuforj and Niktimvo, as well as uncertainty around upcoming trial results and potential regulatory delays.

    Find out about the key risks to this Syndax Pharmaceuticals narrative.

    Next Steps

    If the Syndax Pharmaceuticals story so far sounds compelling, it could be worth moving quickly to review the numbers and sentiment yourself, then examine the 2 key rewards

    Looking for more investment ideas beyond Syndax Pharmaceuticals?

    If Syndax Pharmaceuticals has sharpened your focus, do not stop here. Use the screener tools to quickly surface fresh stocks that fit your style and risk comfort.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.